Synthomer agreed to sell its Czech acrylate monomers business to Mutares, with estimated 2025 revenues of €110 million. The deal removes a cyclical base chemicals unit from Synthomer's portfolio while
Synthomer projects weaker 2025 sales and earnings due to subdued end markets, although cost cuts and a focus on specialty solutions widened EBITDA margins despite tariff challenges.
KLK, holding a 27% stake in Synthomer, will purchase approximately £50 million of the company's trade receivables under a new agreement.
Synthomer forecasts its 2025 earnings will match the prior year, while planning self-help actions to counter soft demand and boost 2026 performance.
ChemBrief